Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2414009
Max Phase: Preclinical
Molecular Formula: C28H46O3
Molecular Weight: 430.67
Molecule Type: Small molecule
Associated Items:
ID: ALA2414009
Max Phase: Preclinical
Molecular Formula: C28H46O3
Molecular Weight: 430.67
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)[C@@H](C)[C@@H]1O
Standard InChI: InChI=1S/C28H46O3/c1-18(9-7-15-27(4,5)31)23-13-14-24-21(10-8-16-28(23,24)6)11-12-22-17-25(29)20(3)26(30)19(22)2/h11-12,18,20,23-26,29-31H,2,7-10,13-17H2,1,3-6H3/b21-11+,22-12-/t18-,20-,23-,24+,25-,26-,28-/m1/s1
Standard InChI Key: PSWKLSOBPNHZSY-FQJGWPOGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 430.67 | Molecular Weight (Monoisotopic): 430.3447 | AlogP: 5.95 | #Rotatable Bonds: 6 |
Polar Surface Area: 60.69 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 3 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.83 | CX LogD: 4.83 |
Aromatic Rings: 0 | Heavy Atoms: 31 | QED Weighted: 0.49 | Np Likeness Score: 2.43 |
1. Konno K, Maki S, Fujishima T, Liu Z, Miura D, Chokki M, Takayama H.. (1998) A novel and practical route to A-ring enyne synthon for 1 alpha,25-dihydroxyvitamin D3 analogs: synthesis of A-ring diastereomers of 1 alpha,25-dihydroxyvitamin D2 and 3-methyl-1,25-dihydroxyvitamin D3., 8 (2): [PMID:9871644] [10.1016/s0960-894x(97)10204-9] |
2. Fujishima T, Liu Z, Miura D, Chokki M, Ishizuka S, Konno K, Takayama H.. (1998) Synthesis and biological activity of 2-methyl-20-epi analogues of 1 alpha,25-dihydroxyvitamin D3., 8 (16): [PMID:9873502] [10.1016/s0960-894x(98)00363-1] |
3. Konno K, Fujishima T, Maki S, Liu Z, Miura D, Chokki M, Ishizuka S, Yamaguchi K, Kan Y, Kurihara M, Miyata N, Smith C, DeLuca HF, Takayama H.. (2000) Synthesis, biological evaluation, and conformational analysis of A-ring diastereomers of 2-methyl-1,25-dihydroxyvitamin D(3) and their 20-epimers: unique activity profiles depending on the stereochemistry of the A-ring and at C-20., 43 (22): [PMID:11063621] [10.1021/jm000261j] |
4. Konno K, Fujishima T, Maki S, Liu Z, Miura D, Chokki M, Ishizuka S, Yamaguchi K, Kan Y, Kurihara M, Miyata N, Smith C, DeLuca HF, Takayama H.. (2000) Synthesis, biological evaluation, and conformational analysis of A-ring diastereomers of 2-methyl-1,25-dihydroxyvitamin D(3) and their 20-epimers: unique activity profiles depending on the stereochemistry of the A-ring and at C-20., 43 (22): [PMID:11063621] [10.1021/jm000261j] |
5. Fujishima T, Nozaki T, Suenaga T.. (2013) Design and synthesis of novel 1,25-dihydroxyvitamin D3 analogues having a spiro-oxetane fused at the C2 position in the A-ring., 21 (17): [PMID:23845283] [10.1016/j.bmc.2013.06.032] |
Source(1):